Related Pages for MANKIND

Option Chain
Max Pain
Put Call Ratio
Option Analytics
Call OI vs Put OI
Call OI Chg vs Put OI Chg
Call Vol vs Put Vol
Vega Divergence
Buildup & Unwinding
Strike Flow
Future Chain
Future Intraday Analysis
Technical
Financials
Chart
About

Search Symbol
MANKIND
Mankind Pharma Limited

2292.9 +57.90 (2.59%)

L: 2222.6 H: 2322.2
Option
- Option
- Option Chain
- Max Pain
- Put Call Ratio
- Option Analytics
Option Analysis
- Option Analysis
- Call OI vs Put OI
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Vega Divergence
- Buildup & Unwinding
- Strike Flow
Futures
- Futures
- Future Chain
- Future Intraday Analysis
Company
- Company
- Technical
- Corporate Events & News
- Financials
- Chart
- About

🎨 Holi Special Offer! Get +30 Free Days on Yearly or +10 Free Days on Quarterly — Ends 8th Mar Midnight. View Plans → 🎨 Holi Offer — Ends 8th Mar - View Plans →

NiftyInvest

Market
Max Pain
Put Call Ratio
Option

Option Chain

Straddle Option Chain

Max Pain

Max Pain Table

Put Call Ratio

Put Call Ratio Table

Option Analytics

Option Screener

Multi Strike OI

Call OI vs Put OI

StrikeFlow: Call vs Put Positioning

Call OI Change vs Put OI Change

Call Vol vs Put Vol

Buildup & Unwinding

Vega Divergence

Strategy Builder

Strategy Simulator
Future
Company
Live News
Pricing
My View
Login
Sign-up

[--[65.84.65.76]--]

MANKIND

Mankind Pharma Limited

2292.9 +57.90 (2.59%)

L: 2222.6 H: 2322.2

0 results

No results found.

MANKIND 2292.9

57.9 (2.59%)

Search symbol e.g. NIFTY, RELIANCE, CRUDEOIL

Corporate Actions
Related News

Loading corporate actions

Related News - MANKIND

Mankind Pharma: Board Approves Closing Mankind Pharma Lanka, With No Ongoing Business Due To New Rules

13 Apr 2026 03:28 PM

Mankind Pharma: Board Approves Closing Mankind Pharma Lanka, With No Ongoing Business Due To New Rules

Mankind Pharma: Morgan Stanley on Mankind Pharma Overweight (Initiated), Target Price Rs 2500 as 11% revenue CAGR, ~25% EPS CAGR, domestic recovery, Bharat Serums and Vaccines optionality and 11–12% IPM growth drive superior risk-reward.

27 Mar 2026 09:03 AM

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

18 Mar 2026 10:02 AM

Mankind Pharma: Purchases Rivotril Brand in India To Boost CNS Treatments; Gains Exclusive Rights For Production, Sales, And Distribution; Enhances Options For Neurological Care.

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines || Unit Operations Continued As Usual During Inspection

09 Feb 2026 03:04 PM

Mankind Pharma: Search And Seizure/Inspection Operation Conducted By Gst Department At Bharat Serums And Vaccines || Unit Operations Continued As Usual During Inspection

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 || BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

09 Feb 2026 03:05 PM

MANKIND PHARMA: OPERATION CONDUCTED FROM FEBRUARY 03 TO FEBRUARY 08, 2026 || BUSINESS OPERATIONS OF BSV CONTINUED AS USUAL DURING SEARCH

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 REVENUE 36B RUPEES VS 32B (YOY)

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) || Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 EBITDA 9.19B RUPEES VS 8.30B (YOY) || Q3 EBITDA MARGIN 25.76% VS 25.7% (YOY)

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

03 Feb 2026 04:29 PM

MANKIND PHARMA: Q3 CONS NET PROFIT 4.1B RUPEES VS 3.8B (YOY); EST 5.1B

Mankind Pharma: Co To Consider Q3 Results On Feb 3

09 Jan 2026 11:56 AM

Mankind Pharma: Co To Consider Q3 Results On Feb 3

Empowering traders with comprehensive investment insights and advanced market analysis tools. Real-time data, intelligent analytics, and cutting-edge trading intelligence for the Indian stock markets.